Ligand Pharmaceuticals has signed a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in Europe, Switzerland, and India. Ligand is eligible to receive sales milestones and royalties on sales.   Ethicor plans to supply oral lasofoxifene as an unlicensed medicinal product to meet the clinical needs of patients when authorized medicines are unsuitable or contraindicated.   “This agreement with Ethicor represents another potential...